The Non-TSX Cannabis Play to Make

Lost in the news when Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) became a U.S.-listed company was the Canadian Securities Exchange’s newest cannabis play — and it’s a good one.

| More on:

Lost in the news when Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) listed on the NYSE was the latest addition to the Cannabis Stock Exchange, legally referred to as the Canadian Securities Exchange.

MedMen Enterprises Inc. (CSE:MMEN) began trading on the CSE May 29 after completing a reverse merger with Ladera Ventures that saw its shareholders end up with one share in MMEN for every 9.263 shares in the predecessor.

A reverse merger, reverse split. How often do you see that? I guess anything’s possible in the uber-growth cannabis industry.

Don’t overlook MedMen

On the surface, this does seem like a cash grab by MedMen CEO Alan Bierman and president Andrew Modlin, who are paid and incentivized handsomely by the company — each executive will earn US$1.5 million annually, receive a US$4 million bonus when it hits an enterprise value of more than US$2 billion, and receive US$40 million in units over the next two years — but the mere fact the duo has been able to bring MedMen this far suggests they’re not just a couple of guys off the street.

Sure, MedMen doesn’t make money, but how many cannabis companies do?

In the latest six months ended December 31, 2017, MedMen generated a loss of US$15 million from net sales of US$3.3 million. Keep in mind that most of the revenue comes from the retailer’s seven California locations.

Bierman’s got much bigger plans.

He’s locating stores in urban markets where marijuana is legal such as Los Angeles, Las Vegas, and New York. Stores range in size from 2,000 to 10,000 square feet depending on the market. Interestingly, where possible, MedMen is also buying the real estate, which makes a lot of sense when you consider it will eventually want to work with commercial banks to obtain non-mortgage loans, rather than issuing more shares.

For example, in February it acquired a dispensary in San Diego plus the real estate the shop sat on for US$20.4 million. In 2017, the dispensary operated as a medical-only dispensary, but it has since been approved for recreational cannabis sales.

At the same time, MedMen paid US$19.4 million to acquire prime Venice Beach real estate and is in the process of relocating another location in southern California to this high-traffic section of Los Angeles.

Looking to be a vertically integrated retailer, it has one 47,000-square-foot cultivation and production facility in northern Nevada with two other 45,000-square-foot facilities planned for New York State and the California desert.

Why do I like it?

If investors are honest with themselves, almost every cannabis play in Canada or the U.S. is a crap-shoot at this point. That even applies to Canopy, despite its 9.9% investment from Constellation Brands, Inc.

Bierman is smart in that he has gone after the high-traffic locations in Beverly Hills and Fifth Avenue to draw the crowds. In that respect, the recreational pot market isn’t much different than the retail shops already located on those exclusive shopping strips.

Instead of making it a sterile medical environment, MedMen is providing a shopping experience that both educates customers while making it pleasant enough to stay longer.

I have no definitive answer whether it will be successful in the long term, but if you’re going to throw down a few thousand on a cannabis company, MedMen seems like as good a bet as any.

I’ll be watching its progress closely.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Will Ashworth has no position in any stocks mentioned.

More on Investing

Target. Stand out from the crowd

2 Canadian Stocks I’m Buying Lots of This Year

I’m looking to snatch up exciting Canadian stocks like VieMed Healthcare Inc. (TSX:VMD) throughout 2023.

Read more »

grow money, wealth build
Dividend Stocks

Got $3,000? 3 TSX Growth Stocks to Buy in January 2023

Top TSX growth stocks that look appealing for 2023.

Read more »

woman data analyze
Dividend Stocks

Need Passive Income? Turn $15,000 Into $851 Annually

This passive-income stock is already climbing higher, up 16% in the last three months! Yet it's still valuable, so you…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

Retirees: 3 Reliable Canadian Dividend Stocks to Buy Now for Passive Income

Top TSX dividend stocks now appear oversold.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.

2 TSX Stocks Safer for Investing in a Recession

These consumer companies will likely beat the broader market averages amid a recession. These stocks offer stability, income, and consistent…

Read more »

Dividend Stocks

For $100 in Passive Income Each Month, Buy 1,500 Shares of This REIT

REITs such as Northwest Healthcare can enable investors create a passive-income stream as well as benefit from capital gains.

Read more »

A colourful firework display
Dividend Stocks

2 Canadian Growth Stocks (With Dividends) to Start 2023 With a Bang

Here are two of the best dividend-paying Canadian growth stocks you can invest in at the start of 2023 and…

Read more »

sale discount best price
Dividend Stocks

4 Insanely Cheap Canadian Stocks to Buy for Passive Income

The recent bear market has created some incredible bargains, especially for those looking for passive income. Here are four cheap…

Read more »